BIOTISSUE OCULAR INC.
MIAMI, FLORIDA

Founded in 1997, BioTissue Ocular Inc. has been a trailblazer in the field of ocular surface and lid margin disease treatment by creating innovative regenerative healing products that set the highest clinical standards. Over its three decades of operation, BioTissue's mission has been to enhance patients' lives through advanced solutions promoting healthy eyes and improved vision. Driven by relentless research and a strong scientific foundation, BioTissue uses cutting-edge technology such as the CryoTek™ Method. This process preserves the natural wound-healing properties of amniotic membranes, solidifying its status in ocular surface reconstruction. Leadership figures like Amy have been pivotal from the start, steering company growth with an emphasis on visionary product quality and state-of-the-art wound care solutions. Notable experts within BioTissue include Dr. Scheffer C. G. Tseng, whose academic background spans institutions like National Taiwan University and the University of California at Los Angeles. His expertise has significantly contributed to advancements in corneal health. Financially fortified by Michael Cornelius's leadership as CFO-with a commendable stint at Stiefel Laboratories-BioTissue ensures enduring fiscal stability. With an aim for preeminence, BioTissue is committed to leading the regenerative biomaterials market through scientific innovation and commercial expansion over the next five years. The company continues to innovate with products like Cliradex towelettes and foaming cleansers, ensuring high standards of eyecare hygiene. Well-regarded as a premier ocular care solution by clinicians worldwide, BioTissue's dedication to placing patient needs first and promoting mutual growth is evident. Their strategic vision includes developing human-origin regenerative biomaterials, underscoring their ongoing contribution to advancing ocular health.